# REZZAYO® (rezafungin) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/rezafungin

> The PDUFA target action date for REZZAYO® (rezafungin), sponsored by CorMedix Inc. (CRMD), is Q1 2027. Status: scheduled.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### When is the REZZAYO® (rezafungin) PDUFA date?

The PDUFA target action date for REZZAYO® (rezafungin), sponsored by CorMedix Inc. (CRMD), is Q1 2027. Status: scheduled. Press release filed with the SEC (EX-99): "The sNDA was submitted by Mundipharma, CorMedix's global development partner, and the FDA has granted Priority Review with a Prescription Drug User Fee Act (PDUFA) target action date in Q1 2027." Last confirmed November 12, 2026. [Calendar and source filings](https://sec-api.dev/pdufa/rezafungin)

Source: Press release filed with the SEC (EX-99), accession 0001213900-26-110477, https://www.sec.gov/Archives/edgar/data/1410098/000121390026110477/ea030895701ex99-1.htm (retrieved 2026-11-12). Last confirmed 2026-11-12. Cite: https://sec-api.dev/pdufa/rezafungin#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | REZZAYO® (rezafungin) |
| Codes |  |
| Sponsor | CorMedix Inc. (CRMD) https://sec-api.dev/companies/crmd/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### April 27, 2026: topline data readout

- Status: completed, positive. Date confidence: exact. Stage: 3.
- First seen 2025-10-20, last confirmed 2026-11-12.
- Press release filed with the SEC (EX-99) (accession 0001410098-26-000020): "•On April 27, 2026, CorMedix announced positive Phase III topline results from the global ReSPECT clinical trial evaluating REZZAYO® (rezafungin for injection) for prophylaxis of invasive fungal diseases in adult patients undergoing allogeneic hematopoietic stem cell transplantation." https://www.sec.gov/Archives/edgar/data/1410098/000141009826000020/crmd_q12026earningspr.htm
- SEC Form 10-Q (accession 0001410098-26-000067): "On April 27, 2026, CorMedix announced positive Phase III topline results from the global ReSPECT clinical trial evaluating REZZAYO (rezafungin for injection) for prophylaxis of invasive fungal diseases in adult patients undergoing allogeneic hematopoietic stem cell transplantation, and if approved by the U.S. Food and Drug Administration (the "FDA"), it is targeting commercialization of REZZAYO in this second indication beginning in 2027." https://www.sec.gov/Archives/edgar/data/1410098/000141009826000067/crmd-20260930.htm
- SEC Form 10-Q (accession 0001410098-26-000056): "On April 27, 2026, CorMedix announced positive Phase III topline results from the global ReSPECT clinical trial evaluating REZZAYO (rezafungin for injection) for prophylaxis of invasive fungal diseases in adult patients undergoing allogeneic hematopoietic stem cell transplantation, and if approved by the U.S. Food and Drug Administration (the "FDA"), it is targeting commercialization of REZZAYO in this second indication beginning in 2027." https://www.sec.gov/Archives/edgar/data/1410098/000141009826000056/crmd-20260630.htm
- SEC Form 10-Q (accession 0001410098-26-000056): "On April 27, 2026, CorMedix announced positive Phase III topline results from the global ReSPECT clinical trial evaluating REZZAYO (rezafungin for injection) for prophylaxis of invasive fungal diseases in adult patients undergoing allogeneic hematopoietic stem cell transplantation, and if approved by the FDA, it is targeting commercialization of REZZAYO in this second indication beginning in 2027." https://www.sec.gov/Archives/edgar/data/1410098/000141009826000056/crmd-20260630.htm
- SEC Form 10-Q (accession 0001410098-26-000021): "On April 27, 2026, CorMedix announced positive Phase III topline results from the global ReSPECT clinical trial evaluating REZZAYO (rezafungin for injection) for prophylaxis of invasive fungal diseases in adult patients undergoing allogeneic hematopoietic stem cell transplantation, and if approved by the U.S. Food and Drug Administration (the "FDA"), it is targeting commercialization of REZZAYO in this second indication beginning in 2027." https://www.sec.gov/Archives/edgar/data/1410098/000141009826000021/crmd-20260331.htm
- SEC Form 10-Q (accession 0001410098-26-000021): "On April 27, 2026, CorMedix announced positive Phase III topline results from the global ReSPECT clinical trial evaluating REZZAYO (rezafungin for injection) for prophylaxis of invasive fungal diseases in adult patients undergoing allogeneic hematopoietic stem cell transplantation, and if approved by the FDA, it is targeting commercialization of REZZAYO in this second indication beginning in 2027." https://www.sec.gov/Archives/edgar/data/1410098/000141009826000021/crmd-20260331.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-26-023881): "Topline results of the Phase III study for REZZAYO are expected in Q2 2026." https://www.sec.gov/Archives/edgar/data/1410098/000121390026023881/ea027968001ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-26-002350): "Topline results of the Phase III study for REZZAYO are expected in Q2 2026." https://www.sec.gov/Archives/edgar/data/1410098/000121390026002350/ea027214901ex99-1_cormedix.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-108716): "Topline results of the Phase III study for REZZAYO are expected in Q2 2026." https://www.sec.gov/Archives/edgar/data/1410098/000121390025108716/ea026513601ex99-1_cormedix.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-100156): "Topline results of the Phase III study for REZZAYO are expected in Q2 2026." https://www.sec.gov/Archives/edgar/data/1410098/000121390025100156/ea026176001ex99-1_cormedix.htm

### 2H 2026: NDA/BLA submission

- Status: scheduled. Date confidence: half.
- First seen 2026-04-27, last confirmed 2026-04-27.
- Press release filed with the SEC (EX-99) (accession 0001213900-26-047748): "The companies anticipate a pre-NDA submission meeting with FDA in the coming months, followed by a target submission of a supplemental New Drug Application (sNDA) to the FDA in 2H26 based on the ReSPECT results." https://www.sec.gov/Archives/edgar/data/1410098/000121390026047748/ea028764001ex99-1.htm

### October 19, 2026: NDA/BLA acceptance

- Status: completed. Date confidence: exact.
- First seen 2026-10-19, last confirmed 2026-11-12.
- Press release filed with the SEC (EX-99) (accession 0001213900-26-110477): "NJ - October 19, 2026 - CorMedix Therapeutics (Nasdaq: CRMD) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Application (sNDA) seeking approval of REZZAYO® (rezafungin for injection)" https://www.sec.gov/Archives/edgar/data/1410098/000121390026110477/ea030895701ex99-1.htm
- SEC Form 10-Q (accession 0001410098-26-000067): "In October 2026, the Company announced that the U.S. Food and Drug Administration ("FDA") has accepted for filing the supplemental New Drug Application ("sNDA") seeking approval of REZZAYO® (rezafungin for injection) for the prophylaxis of invasive fungal disease." https://www.sec.gov/Archives/edgar/data/1410098/000141009826000067/crmd-20260930.htm
- Press release filed with the SEC (EX-99) (accession 0001410098-26-000063): "•CorMedix announced on October 19, 2026, that in collaboration with its global development partner Mundipharma, the FDA accepted for review the submission of the sNDA for an expanded indication of REZZAYO for the prophylaxis of invasive fungal disease." https://www.sec.gov/Archives/edgar/data/1410098/000141009826000063/crmd_q32026earningspr.htm

### Q1 2027: PDUFA date

- Status: scheduled. Date confidence: quarter.
- First seen 2026-10-19, last confirmed 2026-11-12.
- Press release filed with the SEC (EX-99) (accession 0001213900-26-110477): "The sNDA was submitted by Mundipharma, CorMedix's global development partner, and the FDA has granted Priority Review with a Prescription Drug User Fee Act (PDUFA) target action date in Q1 2027." https://www.sec.gov/Archives/edgar/data/1410098/000121390026110477/ea030895701ex99-1.htm
- SEC Form 10-Q (accession 0001410098-26-000067): "The sNDA was submitted by Mundipharma, the Company's global development partner, and the FDA has granted priority review with a Prescription Drug User Fee Act ("PDUFA") target action date in the first quarter of 2027." https://www.sec.gov/Archives/edgar/data/1410098/000141009826000067/crmd-20260930.htm
- Press release filed with the SEC (EX-99) (accession 0001410098-26-000063): "Second, the FDA granted Priority Review to the REZZAYO prophylaxis sNDA, with a PDUFA date in the first quarter of 2027." https://www.sec.gov/Archives/edgar/data/1410098/000141009826000063/crmd_q32026earningspr.htm

### 2H 2027: PDUFA date

- Status: scheduled. Date confidence: half.
- First seen 2026-10-19, last confirmed 2026-10-19.
- Press release filed with the SEC (EX-99) (accession 0001213900-26-110477): "We look forward to working closely with Mundipharma in the coming months ahead of FDA's action date and will begin to prepare for a potential promotional launch in the second half of 2027."" https://www.sec.gov/Archives/edgar/data/1410098/000121390026110477/ea030895701ex99-1.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/rezafungin.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "REZZAYO® (rezafungin) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/rezafungin

```bibtex
@misc{secapidev_pdufa_rezafungin_20261116,
  title        = {REZZAYO® (rezafungin) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/rezafungin}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_rezafungin_20261116","title":"REZZAYO® (rezafungin) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/rezafungin","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
